Safety and efficacy of permafibrate (K-808), a selective peroxisome proliferator-activated receptor alpha modulator, in patients with primary biliary cholangits: twelve-week data from the randomized, placebo-controlled, PEMA-PBC Dose-finding study

Conference Reports for NATAP

EASL - European Association
for the Study of the Liver
Barcelona, Spain
May 27-30, 2026


Safety and efficacy of permafibrate (K-808), a selective peroxisome proliferator-activated receptor alpha modulator, in patients with primary biliary cholangits: twelve-week data from the randomized, placebo-controlled, PEMA-PBC Dose-finding study

	EASL 2026 May 26-30 Barcelona